Profile | GDS2987 / GI_38570061-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 37.6 | 67 |
GSM215244 | HMVEC_vehicle_rep2 | 38.6 | 64 |
GSM215253 | HMVEC_vehicle_rep3 | 35.2 | 66 |
GSM215254 | HMVEC_atorvastatin_rep1 | 53.9 | 69 |
GSM215282 | HMVEC_atorvastatin_rep3 | 45.4 | 66 |
GSM215344 | HMVEC_atorvastatin_rep2 | 43.8 | 66 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | ||
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 23.3 | 43 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 11.8 | 20 |
GSM215294 | HMVEC_SLx2119_rep1 | 50 | 71 |
GSM215295 | HMVEC_SLx2119_rep2 | 4.4 | 9 |
GSM215296 | HMVEC_SLx2119_rep3 | 14.6 | 24 |
GSM215297 | PASMC_vehicle_rep1 | ||
GSM215298 | PASMC_vehicle_rep2 | 6.7 | 11 |
GSM215310 | PASMC_vehicle_rep3 | ||
GSM215311 | PASMC_atorvastatin_rep1 | 34.4 | 51 |
GSM215312 | PASMC_atorvastatin_rep2 | 34.4 | 48 |
GSM215313 | PASMC_atorvastatin_rep3 | ||
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | ||
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 20.7 | 38 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 28.5 | 44 |
GSM215327 | PASMC_SLx2119_rep1 | ||
GSM215328 | PASMC_SLx2119_rep2 | 23.3 | 40 |
GSM215329 | PASMC_SLx2119_rep3 | 12.9 | 25 |
GSM215330 | Fibroblasts_vehicle_rep1 | ||
GSM215331 | Fibroblasts_vehicle_rep2 | 18.1 | 45 |
GSM215332 | Fibroblasts_vehicle_rep3 | 23.6 | 57 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 41 | 66 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 28.9 | 58 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 12.7 | 31 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 34.4 | 65 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 39.2 | 67 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 17.6 | 44 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 14 | 39 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 26.1 | 56 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 7.6 | 20 |